(Q32049893)

5 July 2017

1 reference

title

Dosing and monitoring of low-molecular-weight heparins in special populations (English)

1 reference

5 July 2017

Duplaga BA

1

1 reference

5 July 2017

Rivers CW

series ordinal

2

1 reference

5 July 2017

Nutescu E

series ordinal

3

1 reference

5 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

5 July 2017

1 reference

5 July 2017

volume

21

1 reference

5 July 2017

issue

2

1 reference

5 July 2017

page(s)

218-234

1 reference

Low molecular weight heparins: current use and indications

5 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Low-Molecular-Weight Heparins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Standardization of prothrombin time for laboratory control of oral anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Treatment of deep vein thrombosis with low-molecular-weight heparins: a consensus statement of the Gesellschaft für Thrombose-und Hämostaseforschung (GTH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Clinical uses of low-molecular-weight heparins

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Prophylaxis of postoperative thromboembolism with low molecular weight heparins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Low molecular weight heparin in prevention of perioperative thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Phenprocoumon from a neurosurgical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Frequency of pulmonary embolism in patients who have iliofemoral deep vein thrombosis and are treated with once- or twice-daily low-molecular-weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Low-molecular-weight heparins for acute coronary syndromes: an emergency medicine perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Even

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Low-molecular-weight heparins in the management of acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Body weight does not predict for anti-Xa levels after fixed dose prophylaxis with enoxaparin after orthopedic surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Low molecular weight heparin half life is prolonged in haemodialysed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Pharmacokinetic of a very low molecular weight heparin in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Delayed elimination of enoxaparine in patients with chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Treatment of pulmonary embolism by subcutaneous low-molecular-weight heparin in a hemodialysis patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Venous thromboembolism during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Current concepts of anticoagulant therapy in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Deep venous thrombosis and pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Low-molecular-weight heparins in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Anticoagulation therapy in pediatric patients with sinovenous thrombosis: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

The "Phoenix" ADR database of the Drug Commission of the German Medical Profession--a clinically useful approach to optimize evidence-based medicine in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.2.218.34112

10.1592/PHCO.21.2.218.34112

21 January 2018

Identifiers

DOI

1 reference

5 July 2017

1 reference